Inhibikase Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Inhibikase Therapeutics has a total shareholder equity of $19.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $22.3M and $2.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.94m |
| Equity | US$19.46m |
| Total liabilities | US$2.88m |
| Total assets | US$22.35m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IQT0's short term assets ($22.0M) exceed its short term liabilities ($2.7M).
Long Term Liabilities: IQT0's short term assets ($22.0M) exceed its long term liabilities ($150.0K).
Debt to Equity History and Analysis
Debt Level: IQT0 is debt free.
Reducing Debt: IQT0 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IQT0 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IQT0 has less than a year of cash runway if free cash flow continues to reduce at historical rates of 61.2% each year